Plant ID: NPO7632
Plant Latin Name: Rheum tanguticum
Taxonomy Genus: Rheum
Taxonomy Family: Polygonaceae
NCBI TaxonomyDB:
137226
Plant-of-the-World-Online:
696803-1
Austria; China
TSHR; | |
DRD3; | |
ALPL; TDP1; PIK3CA; PIK3CB; HSD11B1; PGD; HSD11B2; ALOX12; GFER; HSD17B10; NQO2; ALOX15; USP2; APEX1; | |
BCL2; | |
AXL; MAPK1; KDR; SRC; IGF1R; PTK2; ALK; | |
CA2; CA12; CA9; CA7; CA14; | |
ESR1; | |
RXRA; | |
KDM4E; | |
PTGS2; | |
MMP9; MMP1; MMP2; | |
NFKB1; | |
FUT7; | |
LMNA; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
Enzyme_unclassified | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | P80365 | CHEMBL3746 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 2 group B | RXRA | Retinoid X receptor alpha | P19793 | CHEMBL2061 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.432E-10 | 3.118E-07 | CA12, CA14, CA2, CA7, CA9 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.369E-08 | 1.104E-05 | AXL, KDR, PIK3CA, PIK3CB, PTK2, SRC |
BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 4.177E-08 | 2.664E-05 | BCL2, PIK3CA, PTK2, SRC |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.931E-08 | 2.759E-05 | CA12, CA14, CA2, CA7, CA9 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 7.893E-08 | 4.092E-05 | ALPL, APEX1, CYP1A1, CYP1B1, ESR1, MAPK1, NFKB1, PTGS2, SRC |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.009E-07 | 8.043E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 4.322E-07 | 1.448E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, PTGS2, SRC |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.308E-06 | 3.352E-04 | CA12, CA2, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.309E-06 | 3.352E-04 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.473E-06 | 3.687E-04 | CA12, CA2, CA7, CA9, ESR1, L3MBTL1, MMP1, MMP2, MMP9, NQO2, RXRA |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.600E-06 | 3.918E-04 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 1.633E-06 | 3.952E-04 | MMP2, MMP9, PTGS2, RXRA |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 1.797E-06 | 4.221E-04 | IGF1R, PIK3CA, PIK3CB |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 2.814E-06 | 6.190E-04 | ALPL, AXL, CYP1A1, CYP1A2, NFKB1, PTGS2, SRC |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.259E-06 | 6.986E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 3.510E-06 | 7.280E-04 | ALOX12, ALOX15, CYP1A1, CYP3A4, HSD11B1, HSD11B2, PIK3CA, PIK3CB, PTGS2 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 3.888E-06 | 7.575E-04 | IGF1R, KDR, PTK2, SRC |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 4.973E-06 | 8.560E-04 | AXL, MAPK1, PIK3CA, PIK3CB, SRC |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.071E-06 | 8.560E-04 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.071E-06 | 8.560E-04 | ALOX12, ALOX15 |
BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 5.925E-06 | 9.556E-04 | ALOX15, ALPL, BCL2, MMP2, MMP9 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 6.049E-06 | 9.685E-04 | ALOX12, ALOX15, PTGS2 |
BP | GO:0008152; metabolic process | GO:0001934; positive regulation of protein phosphorylation | 6.543E-06 | 1.018E-03 | ALK, ALOX15, BCL2, KDR, MAPK1, MMP9, PIK3CA, PIK3CB, PTGS2, PTK2, SRC |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 7.280E-06 | 1.109E-03 | BCL2, CA2, CA7, DRD3, KDR, SRC |
BP | GO:0009987; cellular process | GO:0038096; Fc-gamma receptor signaling pathway involved in phagocytosis | 1.125E-05 | 1.600E-03 | MAPK1, PIK3CA, PIK3CB, PTK2, SRC |
MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 1.186E-05 | 1.656E-03 | ALK, AXL, IGF1R, KDR |
BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 1.425E-05 | 1.881E-03 | CA2, PTGS2, SRC |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.425E-05 | 1.881E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.519E-05 | 1.934E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.519E-05 | 1.934E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.519E-05 | 1.934E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.519E-05 | 1.934E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.519E-05 | 1.934E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0019216; regulation of lipid metabolic process | 1.645E-05 | 2.071E-03 | CYP1A1, DRD3, NFKB1, PTGS2, PTK2, RXRA, SRC |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.892E-05 | 2.352E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.395E-05 | 2.839E-03 | AXL, PIK3CA, PIK3CB, PTK2, SRC |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.034E-05 | 3.388E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.034E-05 | 3.388E-03 | CYP1A2, CYP3A4 |
CC | GO:0016020; membrane | GO:0005886; plasma membrane | 3.067E-05 | 3.399E-03 | ALK, ALOX12, ALOX15, ALPL, AXL, CA12, CA14, CA2, CA9, DRD3, ESR1, HSD17B10, IGF1R, KDR, L3MBTL1, MAPK1, MMP2, PIK3CA, PIK3CB, PTK2, SRC, TDP1, TSHR |
BP | GO:0050896; response to stimulus | GO:0031667; response to nutrient levels | 3.318E-05 | 3.577E-03 | ALPL, BCL2, CYP1A1, HSD11B2, MAPK1, PTGS2, SRC |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 4.741E-05 | 4.757E-03 | CYP1A2, MAPK1, MMP9 |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 5.049E-05 | 4.930E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 5.049E-05 | 4.930E-03 | CYP1A1, CYP3A4 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 6.410E-05 | 6.043E-03 | BCL2, MMP9, PTGS2, SRC |
BP | GO:0065007; biological regulation | GO:0030641; regulation of cellular pH | 6.410E-05 | 6.043E-03 | BCL2, CA2, CA7, MAPK1 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 7.563E-05 | 6.919E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.563E-05 | 6.919E-03 | CYP1A2, CYP3A4 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 9.122E-05 | 8.107E-03 | BCL2, LMNA, PTGS2, SRC |
BP | GO:0050896; response to stimulus | GO:0034097; response to cytokine | 9.433E-05 | 8.316E-03 | ALOX15, AXL, BCL2, MAPK1, NFKB1, PTGS2, SRC |
MF | GO:0003824; catalytic activity | GO:0032451; demethylase activity | 9.517E-05 | 8.356E-03 | CYP1A1, CYP1A2, KDM4E |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.057E-04 | 8.889E-03 | CYP1A2, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0035005; 1-phosphatidylinositol-4-phosphate 3-kinase activity | 1.057E-04 | 8.889E-03 | PIK3CA, PIK3CB |
BP | GO:0050896; response to stimulus | GO:0035094; response to nicotine | 1.107E-04 | 9.197E-03 | BCL2, MAPK1, NFKB1 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.773E-11 | 2.943E-09 | RXRA, PIK3CA, MMP1, MMP2, BCL2, MAPK1, PIK3CB, PTGS2, MMP9, NFKB1, PTK2, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.708E-11 | 2.664E-09 | PIK3CA, SRC, MMP2, KDR, MAPK1, PIK3CB, ESR1, MMP9, PTK2, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 6.037E-11 | 3.139E-09 | PIK3CA, SRC, KDR, MAPK1, PIK3CB, PTGS2, PTK2 |
09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 7.140E-10 | 2.228E-08 | RXRA, PIK3CA, BCL2, PIK3CB, PTGS2, NFKB1, PTK2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.937E-09 | 5.036E-08 | PIK3CA, SRC, MMP2, MAPK1, PIK3CB, ESR1, MMP9 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.115E-08 | 2.120E-07 | PIK3CA, SRC, MAPK1, PIK3CB, ESR1, NFKB1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.223E-08 | 2.120E-07 | PIK3CA, SRC, KDR, BCL2, MAPK1, PIK3CB, PTK2, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.955E-09 | 6.586E-08 | HSD11B1, HSD11B2, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 4.594E-08 | 5.119E-07 | RXRA, PIK3CA, KDR, BCL2, MAPK1, PIK3CB, PTK2, NFKB1, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.923E-08 | 3.799E-07 | PIK3CA, SRC, BCL2, MAPK1, PIK3CB, MMP9, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 4.034E-08 | 4.840E-07 | PIK3CA, BCL2, MAPK1, PIK3CB, NFKB1, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 8.626E-08 | 8.971E-07 | PIK3CA, MMP2, BCL2, MAPK1, PIK3CB, NFKB1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.473E-10 | 9.643E-09 | CA12, CA2, CA7, CA9, CA14 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.458E-08 | 3.799E-07 | HSD11B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.880E-08 | 3.799E-07 | MMP1, SRC, MMP2, MAPK1, MMP9 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 9.701E-08 | 9.458E-07 | PIK3CA, BCL2, MAPK1, PIK3CB, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.437E-07 | 1.245E-06 | PIK3CA, MAPK1, PIK3CB, PTGS2, MMP9, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.433E-07 | 1.245E-06 | ALK, RXRA, PIK3CA, MAPK1, PIK3CB |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.181E-07 | 1.791E-06 | RXRA, PIK3CA, SRC, MAPK1, PIK3CB, ESR1 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 5.992E-07 | 4.451E-06 | PIK3CA, LMNA, BCL2, MAPK1, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 1.318E-06 | 9.343E-06 | PIK3CA, SRC, MAPK1, PIK3CB, PTK2 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.479E-07 | 4.274E-06 | HSD11B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 3.240E-06 | 2.106E-05 | PIK3CA, SRC, MAPK1, PIK3CB, NFKB1, PTK2 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 3.551E-06 | 2.216E-05 | PIK3CA, BCL2, CYP1B1, MAPK1, PTGS2, MMP9, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 6.489E-06 | 3.265E-05 | PIK3CA, SRC, KDR, MAPK1, PIK3CB, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 5.932E-06 | 3.265E-05 | PIK3CA, BCL2, MAPK1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 6.441E-06 | 3.265E-05 | PIK3CA, BCL2, MAPK1, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 9.851E-06 | 4.520E-05 | PIK3CA, KDR, MAPK1, PIK3CB, NFKB1, IGF1R |
09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 5.932E-06 | 3.265E-05 | PIK3CA, MMP2, PIK3CB, MMP9, PTK2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 6.441E-06 | 3.265E-05 | PIK3CA, BCL2, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.063E-05 | 4.608E-05 | RXRA, PIK3CA, MAPK1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.358E-06 | 2.615E-05 | CYP1A1, CYP1B1, PTGS2, IGF1R |
09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 1.584E-06 | 1.074E-05 | HSD11B2, PIK3CA, MAPK1, PIK3CB |
09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 2.446E-05 | 9.084E-05 | PIK3CA, SRC, MAPK1, PIK3CB, PTGS2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 6.884E-06 | 3.356E-05 | PIK3CA, PIK3CB, PTGS2, TSHR |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 7.391E-06 | 3.494E-05 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 5.675E-05 | 1.884E-04 | HSD11B1, FUT7, CYP1A2, ALOX15, CYP1A1, ALPL, ALOX12, PTGS2, PGD, CYP3A4, HSD17B10 |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.251E-05 | 5.274E-05 | PIK3CA, MAPK1, PIK3CB, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.036E-05 | 4.608E-05 | PIK3CA, BCL2, MAPK1, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.778E-05 | 7.112E-05 | PIK3CA, MAPK1, PIK3CB, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.329E-05 | 5.457E-05 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.985E-05 | 7.554E-05 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 4.564E-05 | 1.582E-04 | RXRA, MMP9, NFKB1, PTK2, IGF1R |
09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 1.985E-05 | 7.554E-05 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 7.348E-05 | 2.248E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1, TSHR |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 6.331E-05 | 2.015E-04 | PIK3CA, MAPK1, PIK3CB, IGF1R |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 5.379E-05 | 1.824E-04 | PIK3CA, PIK3CB, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 8.455E-05 | 2.438E-04 | PIK3CA, SRC, MAPK1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 6.331E-05 | 2.015E-04 | PIK3CA, SRC, ALOX12, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 2.581E-05 | 9.364E-05 | PIK3CA, SRC, PIK3CB, PTK2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 6.850E-05 | 2.137E-04 | PIK3CA, PIK3CB, NFKB1, PTK2 |
09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 1.035E-04 | 2.784E-04 | PIK3CA, SRC, MAPK1, PIK3CB, PTK2 |
09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.028E-04 | 2.784E-04 | PIK3CA, BCL2, MAPK1, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 7.981E-05 | 2.349E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 7.981E-05 | 2.349E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 8.595E-05 | 2.438E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 1.481E-04 | 3.852E-04 | PIK3CA, SRC, MAPK1, PIK3CB |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.064E-04 | 2.814E-04 | ALOX15, MAPK1, ALOX12, PTGS2 |
09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 2.006E-04 | 5.032E-04 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 2.652E-04 | 6.365E-04 | PIK3CA, MAPK1, PIK3CB, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.065E-04 | 5.032E-04 | PIK3CA, MAPK1, PIK3CB, IGF1R |
09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.105E-04 | 7.252E-04 | PIK3CA, BCL2, MAPK1, PIK3CB |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 3.351E-04 | 7.688E-04 | RXRA, PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 9.996E-04 | 1.925E-03 | PIK3CA, BCL2, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 5.851E-04 | 1.155E-03 | PIK3CA, MAPK1, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 6.237E-04 | 1.216E-03 | SRC, BCL2, MAPK1, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 3.322E-03 | 5.759E-03 | PIK3CA, PIK3CB, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04650 | Natural killer cell mediated cytotoxicity | 3.254E-03 | 5.704E-03 | PIK3CA, MAPK1, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 5.054E-03 | 8.387E-03 | PIK3CA, BCL2, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 3.901E-03 | 6.615E-03 | PIK3CA, MAPK1, PIK3CB |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.773E-03 | 3.216E-03 | PIK3CA, PIK3CB, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 3.533E-03 | 6.056E-03 | PIK3CA, MAPK1, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 5.892E-03 | 9.676E-03 | PIK3CA, MAPK1, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 2.559E-03 | 4.537E-03 | PIK3CA, PIK3CB, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 1.424E-03 | 2.614E-03 | PIK3CA, MAPK1, PIK3CB |
09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 1.054E-03 | 2.006E-03 | SRC, MMP2, MAPK1 |
09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 1.123E-03 | 2.085E-03 | PIK3CA, MAPK1, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 1.123E-03 | 2.085E-03 | BCL2, PTGS2, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 3.115E-04 | 7.252E-04 | PIK3CA, MAPK1, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 4.506E-04 | 9.372E-04 | PIK3CA, MAPK1, PIK3CB |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 3.769E-04 | 8.399E-04 | PIK3CA, PIK3CB, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 5.549E-04 | 1.124E-03 | MAPK1, PTGS2, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.314E-04 | 9.094E-04 | PIK3CA, MAPK1, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 4.127E-04 | 8.819E-04 | PIK3CA, MAPK1, PIK3CB |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 5.775E-04 | 1.155E-03 | SRC, MAPK1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 2.036E-04 | 5.032E-04 | PIK3CA, MAPK1, PIK3CB |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.945E-04 | 8.548E-04 | CYP1A2, CYP1A1, CYP3A4 |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 5.115E-04 | 1.050E-03 | RXRA, CA2, CYP3A4 |
09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 3.945E-04 | 8.548E-04 | SRC, MAPK1, NFKB1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.432E-04 | 7.759E-04 | ALOX15, ALOX12, PTGS2 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 1.603E-04 | 4.101E-04 | PIK3CA, MAPK1, PIK3CB |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 9.273E-05 | 2.583E-04 | CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.488E-05 | 1.237E-04 | CYP1A2, ALOX15, CYP3A4 |
09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 4.410E-03 | 7.397E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 1.849E-03 | 3.316E-03 | RXRA, MAPK1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; BCL2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
C00-D49: Neoplasms | Colon cancer | C50 | ALPL; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; MMP9; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; PIK3CA; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
NA: NA | Menopausal disorder | NA | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; SRC; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; IGF1R; KDR; NQO2; CA9; BCL2; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; SRC; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Cutaneous T-cell lymphoma | C84.0, C84.1 | RXRA; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; IGF1R; PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; MMP2; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
C00-D49: Neoplasms | AML | NA | KDR; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; PTGS2; MMP2; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | PTK2; IGF1R; PIK3CA; KDR; MMP9; MAPK1; PIK3CB; SRC; MMP2; CA9; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PTK2; IGF1R; PIK3CA; KDR; NFKB1; MMP9; MAPK1; PTGS2; PIK3CB; SRC; NQO2; MMP2; CA9; BCL2; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD3; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; MMP1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; |
NA: NA | Rheumatold arthritis | NA | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; MMP1; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
NA: NA | Edema | NA | CA2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; MMP2; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD3; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | IGF1R; KDR; AXL; PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; DRD3; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | IGF1R; KDR; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | BCL2; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; BCL2; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
NA: NA | Joint and muscular pain | NA | PTGS2; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; HSD11B2; NFKB1; PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; BCL2; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; BCL2; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |